Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
Enanta Pharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: January 20, 2023
Enanta Pharmaceuticals reported fiscal year 2022 executive compensation information on January 20, 2023.
In 2022, five executives at Enanta Pharmaceuticals received on average a compensation package of $3.8M, a 45% increase compared to previous year.
Average pay of disclosed executives at Enanta Pharmaceuticals
Jay R. Luly, Chief Executive Officer, received $7.3M in total, which increased by 37% compared to 2021. 51% of Luly's compensation, or $3.7M, was in option awards. Luly also received $483K in non-equity incentive plan, $725K in salary, $2.3M in stock awards, as well as $19K in other compensation.
For fiscal year 2022, the median employee pay was $249,345 at Enanta Pharmaceuticals. Therefore, the ratio of Jay R. Luly's pay to the median employee pay was 29 to one.
Scott T. Rottinghaus, Chief Medical Officer, received a compensation package of $4.4M. 60% of the compensation package, or $2.6M, was in option awards.
Yat Sun Or, Chief Scientific Officer, earned $2.5M in 2022, a 24% increase compared to previous year.
Nathaniel S. Gardiner, General Counsel, received $2.4M in 2022, which increases by 26% compared to 2021.
Paul J. Mellett, Chief Financial Officer, earned $2.4M in 2022, a 26% increase compared to previous year.
Enanta Pharmaceuticals' fiscal year ends on September 30.
Related executives
You may also like
Source: SEC filing on January 20, 2023.